Dentium Launches bright Implant and OSTEON™ Xeno at DenTech China 2025

Strengthening Market Presence and Competitiveness in China

Shanghai Launch Draws Strong Local Attention to bright Implant and OSTEON™ Xeno

Dentium successfully launched bright Implant and OSTEON™ Xeno, both of which have completed regulatory approval in China, at DenTech China 2025, held in Shanghai from October 23 to 25. DenTech China, now in its 28th year, is the largest international dental exhibition in China and one of Asia’s most influential dental platforms, attracting over 800 dental companies from more than 30 countries and approximately 150,000 visitors.

As a key launch stage for global dental brands entering the Chinese market, the exhibition featured the latest dental materials, equipment, digital technologies, and clinical education programs. Under the theme of “Integrated, Practice-Oriented Treatment and Surgery,” Dentium presented an experiential exhibition concept that connected implants, GBR, and digital solutions into a single, streamlined clinical workflow.

bright Implant Launch: Short & Narrow Concept for Efficient Surgery

The highlight of Dentium’s presence at DenTech China 2025 was the launch of the bright Implant Short & Narrow lineup.
Designed as a next-generation implant system optimized for challenging anatomical conditions such as narrow alveolar ridges, bright Implant enables minimally invasive surgical approaches that reduce patient burden while significantly shortening surgical time.

With simplified protocols and reduced chair time, bright Implant helps lower overall treatment costs by minimizing patient visits. Its precise drilling guide system and shortened healing period further contribute to reduced patient stress. These clinical advantages provide greater procedural convenience for clinicians and faster recovery with lower financial burden for patients, positioning bright Implant as an innovative solution that delivers tangible value to both practitioners and patients.

Already widely used in the Korean market with a strong track record of clinical reliability, bright Implant has demonstrated stable outcomes across a wide range of cases, earning trust from both clinicians and patients. Building on these proven clinical results, the product has now officially obtained NMPA approval in China, marking a major milestone for Dentium’s full-scale entry into the Chinese implant market. As the first public unveiling following regulatory approval, bright Implant attracted significant attention from local clinicians, with Dentium’s booth drawing heavy traffic from visitors eager to explore the implant design and surgical workflow firsthand.

OSTEON™ Xeno Approved in China: Completing a Comprehensive GBR Portfolio

Also newly approved in China, OSTEON™ Xeno is a xenogeneic bone substitute designed to closely mimic the micro-porous structure of human bone, supporting excellent osteoconductivity and predictable bone regeneration. Its highly interconnected pore structure facilitates cellular and vascular infiltration, while its volume stability and optimized handling properties enhance clinical usability.

With the addition of OSTEON™ Xeno, Dentium China has now established a complete GBR (Guided Bone Regeneration) solution portfolio, encompassing:

• Synthetic bone substitutes (OSTEON II, OSTEON 3, OSTEON 3 Collagen),

• Xenogeneic bone substitute (OSTEON™ Xeno), and

• Resorbable collagen membranes (Collagen Membrane).

This comprehensive lineup enables clinicians to manage the entire GBR process—from bone defect reconstruction to membrane stabilization—using Dentium’s integrated solutions alone. The completion of this full-spectrum GBR portfolio underscores Dentium’s competitiveness in the Chinese market and reinforces its capability to provide clinically reliable, end-to-end regenerative solutions.